Related references
Note: Only part of the references are listed.Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
Joseph Marascio et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial
John L. Gore et al.
PRACTICAL RADIATION ONCOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
Scott E. Eggener et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Edouard J. Trabulsi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.
Anis Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.
Felix Y Feng et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting
Lauren E. Howard et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN.
Felix Y Feng et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy
Alejandro Berlin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.
Felix Y. Feng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement
Matthew R. Cooperberg et al.
EUROPEAN UROLOGY (2019)
Prospective randomized trial of genomic classifier impact on treatment decisions in patients at high risk of recurrence following radical prostatectomy (G-MINOR).
Todd Matthew Morgan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Intratumor heterogeneity in prostate cancer
Shalini S. Yadav et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Decipher Test Impacts Decision Making Among Patients Considering Adjuvant and Salvage Treatment After Radical Prostatectomy: Interim Results From the Multicenter Prospective PRO-IMPACT Study
John L. Gore et al.
CANCER (2017)
Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer
A. E. Ross et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
Marco Moschini et al.
BMC MEDICINE (2016)
Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement
Lesley A. Stewart et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery
Ketan K. Badani et al.
BJU INTERNATIONAL (2015)
Influence of a genomic classifier on post-operative treatment decisions in high-risk prostate cancer patients: results from the PRO-ACT study
Steven N. Michalopoulos et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy
Nicholas Erho et al.
PLOS ONE (2013)
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
Jack Cuzick et al.
LANCET ONCOLOGY (2011)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Genetic progression and the waiting time to cancer
Niko Beerenwinkel et al.
PLOS COMPUTATIONAL BIOLOGY (2007)
Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile
AY Liu et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Share Paper
